Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma
Abstract As patients receiving definitive chemoradiotherapy (dCRT) for oesophageal squamous cell carcinoma (ESCC) are heterogeneous, we aimed to identify prognostic factors and failure patterns after dCRT. From 2006 to 2015, 327 patients who received dCRT for ESCC were reviewed. Treatment response t...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.3783 |
| _version_ | 1818425940880916480 |
|---|---|
| author | Hyehyun Jeong Hyeon‐Su Im Yeonghak Bang Yong‐Hee Kim Hyeong Ryul Kim Hyun Joo Lee Hwoon‐Yong Jung Gin Hyug Lee Ho June Song Do Hoon Kim Kee Don Choi Jeong Hoon Lee Ji Yong Ahn Hee Kyong Na Jin‐Sook Ryu Jihoon Kang Sung‐Bae Kim Jong Hoon Kim Sook Ryun Park |
| author_facet | Hyehyun Jeong Hyeon‐Su Im Yeonghak Bang Yong‐Hee Kim Hyeong Ryul Kim Hyun Joo Lee Hwoon‐Yong Jung Gin Hyug Lee Ho June Song Do Hoon Kim Kee Don Choi Jeong Hoon Lee Ji Yong Ahn Hee Kyong Na Jin‐Sook Ryu Jihoon Kang Sung‐Bae Kim Jong Hoon Kim Sook Ryun Park |
| author_sort | Hyehyun Jeong |
| collection | DOAJ |
| description | Abstract As patients receiving definitive chemoradiotherapy (dCRT) for oesophageal squamous cell carcinoma (ESCC) are heterogeneous, we aimed to identify prognostic factors and failure patterns after dCRT. From 2006 to 2015, 327 patients who received dCRT for ESCC were reviewed. Treatment response to dCRT was evaluated based on EORTC‐PET criteria with endoscopy and CT results. After dCRT, 296 patients (90.5%) achieved disease stabilisation, with 132 cases of complete response (CR) (40.4%), 158 of partial response (PR) (48.3%) and 6 of stable disease (SD) (1.8%); 31 patients (9.5%) had progressive disease (PD). Median overall survival (OS) from response evaluation was 24.0 months in the overall population. Post‐treatment clinical response was the most significant prognostic factor for OS in the multivariate analysis (median OS, 65.0 months for CR, 17.3 months for PR, 4.4 months for SD and 4.0 months for PD; p < 0.0001). Median progression‐free survival (PFS) in 296 patients who achieved disease stabilisation was 13.1 months, and only clinical response was a significant factor in the multivariate analysis. The median PFS of CR, PR and SD patients were 36.9, 9.2 and 2.8 months, respectively (p < 0.0001). The clinical response was also significantly associated with the predominant failure pattern (locoregional failure [81.6%] in the initial non‐PD group vs. distant metastasis [87.1%] in the initial PD group [p < 0.0001]). In conclusion, definitive chemoradiotherapy‐treated ESCC patients showed highly different prognoses after treatment especially according to the clinical response to chemoradiotherapy. |
| first_indexed | 2024-12-14T14:21:56Z |
| format | Article |
| id | doaj.art-835b55644d344114b53f37f309d07915 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-14T14:21:56Z |
| publishDate | 2021-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-835b55644d344114b53f37f309d079152022-12-21T22:58:02ZengWileyCancer Medicine2045-76342021-03-011051745175810.1002/cam4.3783Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinomaHyehyun Jeong0Hyeon‐Su Im1Yeonghak Bang2Yong‐Hee Kim3Hyeong Ryul Kim4Hyun Joo Lee5Hwoon‐Yong Jung6Gin Hyug Lee7Ho June Song8Do Hoon Kim9Kee Don Choi10Jeong Hoon Lee11Ji Yong Ahn12Hee Kyong Na13Jin‐Sook Ryu14Jihoon Kang15Sung‐Bae Kim16Jong Hoon Kim17Sook Ryun Park18Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Thoracic and Cardiovascular Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Thoracic and Cardiovascular Surgery Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Radiology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Gastroenterology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Nuclear Medicine Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Radiation Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of KoreaAbstract As patients receiving definitive chemoradiotherapy (dCRT) for oesophageal squamous cell carcinoma (ESCC) are heterogeneous, we aimed to identify prognostic factors and failure patterns after dCRT. From 2006 to 2015, 327 patients who received dCRT for ESCC were reviewed. Treatment response to dCRT was evaluated based on EORTC‐PET criteria with endoscopy and CT results. After dCRT, 296 patients (90.5%) achieved disease stabilisation, with 132 cases of complete response (CR) (40.4%), 158 of partial response (PR) (48.3%) and 6 of stable disease (SD) (1.8%); 31 patients (9.5%) had progressive disease (PD). Median overall survival (OS) from response evaluation was 24.0 months in the overall population. Post‐treatment clinical response was the most significant prognostic factor for OS in the multivariate analysis (median OS, 65.0 months for CR, 17.3 months for PR, 4.4 months for SD and 4.0 months for PD; p < 0.0001). Median progression‐free survival (PFS) in 296 patients who achieved disease stabilisation was 13.1 months, and only clinical response was a significant factor in the multivariate analysis. The median PFS of CR, PR and SD patients were 36.9, 9.2 and 2.8 months, respectively (p < 0.0001). The clinical response was also significantly associated with the predominant failure pattern (locoregional failure [81.6%] in the initial non‐PD group vs. distant metastasis [87.1%] in the initial PD group [p < 0.0001]). In conclusion, definitive chemoradiotherapy‐treated ESCC patients showed highly different prognoses after treatment especially according to the clinical response to chemoradiotherapy.https://doi.org/10.1002/cam4.3783clinical responsedefinitive chemoradiotherapyoesophageal cancerprognosis |
| spellingShingle | Hyehyun Jeong Hyeon‐Su Im Yeonghak Bang Yong‐Hee Kim Hyeong Ryul Kim Hyun Joo Lee Hwoon‐Yong Jung Gin Hyug Lee Ho June Song Do Hoon Kim Kee Don Choi Jeong Hoon Lee Ji Yong Ahn Hee Kyong Na Jin‐Sook Ryu Jihoon Kang Sung‐Bae Kim Jong Hoon Kim Sook Ryun Park Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma Cancer Medicine clinical response definitive chemoradiotherapy oesophageal cancer prognosis |
| title | Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma |
| title_full | Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma |
| title_fullStr | Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma |
| title_full_unstemmed | Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma |
| title_short | Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma |
| title_sort | analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma |
| topic | clinical response definitive chemoradiotherapy oesophageal cancer prognosis |
| url | https://doi.org/10.1002/cam4.3783 |
| work_keys_str_mv | AT hyehyunjeong analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT hyeonsuim analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT yeonghakbang analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT yongheekim analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT hyeongryulkim analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT hyunjoolee analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT hwoonyongjung analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT ginhyuglee analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT hojunesong analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT dohoonkim analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT keedonchoi analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT jeonghoonlee analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT jiyongahn analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT heekyongna analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT jinsookryu analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT jihoonkang analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT sungbaekim analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT jonghoonkim analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma AT sookryunpark analysisofclinicaloutcomesandprognosticfactorsinpatientstreatedwithdefinitivechemoradiotherapyforoesophagealsquamouscellcarcinoma |